Furthermore, we showed that there is a significant interaction between IL17A and IL17F polymorphisms, treatments (surgery, chemotherapy and radiotherapy) and TNM stage of the disease in CRC patients (Table 5). This evidence concerns the gene IL17F and colorectal carcinoma.